Guillain-Barré syndrome associated with COVID-19 infection: a case from the UK

BMJ Case Rep. 2020 Jul 8;13(7):e236536. doi: 10.1136/bcr-2020-236536.

Abstract

Originating from Wuhan, China, COVID-19 has rapidly spread worldwide. Neurological manifestations are more commonly associated with severe COVID-19 infection. Guillain-Barré syndrome (GBS) is a rare immune-mediated postinfectious neuropathy. It has been reported as a possible rare complication of COVID-19. We report a case of GBS associated with COVID-19 in the UK.

Keywords: infectious diseases; neurology; peripheral nerve disease.

Publication types

  • Case Reports

MeSH terms

  • Betacoronavirus* / isolation & purification
  • Betacoronavirus* / pathogenicity
  • COVID-19
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / physiopathology
  • Diagnostic Techniques, Neurological
  • Guillain-Barre Syndrome* / diagnosis
  • Guillain-Barre Syndrome* / etiology
  • Guillain-Barre Syndrome* / physiopathology
  • Guillain-Barre Syndrome* / therapy
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunologic Factors / administration & dosage
  • Intubation, Gastrointestinal / methods
  • Lower Extremity* / innervation
  • Lower Extremity* / physiopathology
  • Male
  • Middle Aged
  • Neuralgia / etiology
  • Neuralgia / therapy
  • Neurologic Examination / methods
  • Neurological Rehabilitation
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / physiopathology
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors